Please login to the form below

Not currently logged in

Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Hopes to leapfrog rivals


Eli Lilly’s IL-23 inhibitor mirikizumab is trailing the field in lead indication psoriasis – where it looks set to be fifth to market – but could leapfrog some of its rivals in Crohn’s disease.

Lilly has just presented phase 2 results with mirikizumab in moderate to severe Crohn’s – a form of inflammatory bowel disease – which reveal significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo.

That included an endoscopic response rate of 43.8% for patients on a 1,000mg dose of the IL-23 antibody, compared to 10.9% of the placebo group. Other doses of mirikizumab – 200mg and 600mg – achieved endoscopic response rates of 25.8% and 37.5% respectively.

Similar benefits on endoscopic remission rates and patient-reported remissions, plus a fairly clean safety profile, have prompted Lilly to accelerate plans for a phase 3 trial in Crohn’s later this year. The data was presented at this week’s Digestive Disease Week (DDW) medical conference in San Diego.

Crohn’s could be an important indication for Lilly, as mirikizumab is very much playing catch-up in the IL-23 inhibitor category when it comes to psoriasis.

First to market was Johnson & Johnson’s dual IL-12/IL-23 inhibitor Stelara (ustekinumab) for psoriasis, which rapidly achieved blockbuster status with add-on indications in psoriatic arthritis and Crohn’s and made $4bn in sales last year.

Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all already FDA-approved for psoriasis and require fewer injections than Stelara with safety and efficacy that is at least as good. Tremfya also has data suggesting it works in Stelara-resistant psoriasis.

Lilly’s antibody is still in phase 3 for psoriasis, well behind the leaders, but IBD presents a greater opportunity for the drug. With Stelara already available for Crohn’s, Lilly is hoping to be among the leaders to market in this indication, although as Tremfya and Skyrizi are already in phase 3 it will have to move quickly.

Mirikizumab is however already in three phase 3 ulcerative colitis trials that will start generating results next year, and has a chance of being first to market in this indication – although once again it is in a race with Skyrizi, which also has phase 3 trials ongoing in this setting.

"Following last year's presentation of positive phase 2 results for mirikizumab for the treatment of moderate- to severe ulcerative colitis, we are excited to return to DDW to present more positive data for mirikizumab in patients with chronic, inflammatory gastrointestinal conditions,” said Lilly’s head of immunology R&D Lotus Mallbris.

“As we continue to advance the science of gastroenterology, we are hopeful that mirikizumab helps us raise the standard and make remission possible for people living with immune-mediated diseases like Crohn's disease.”

Article by
Phil Taylor

22nd May 2019

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...